

***In the Specification:***

Please amend the specification as shown:

Please delete the paragraph on page 11, lines 19-27 and replace it with the following paragraph:

Synthetic peptides representing immunodominant T-cell epitopes can also act as carriers in polysaccharide and oligosaccharide conjugates. The peptide carriers include polypeptides containing multiple T-cell epitopes addressing the extensive polymorphism of HLA molecules (Paradiso et al., Vaccine Res., 1993, 2, 239-248), and universal T-helper epitopes compatible with human use. Exemplary T-helper epitopes include but are not limited to natural epitopes characterized from tetanus toxoid (Valmori et al., J. Immunol., 1992, 149, 717-721) and non-natural epitopes or engineered epitopes such as the pan HLA DR-binding epitope PADRE (KXVAAWTLKAA (***SEQ ID NO: 41***); Immunity, 1994 1, 751-761).

Please delete the paragraph on page 45, line 17 and replace it with the following paragraph:

Figure 17 : Retrosynthetic analysis of the target conjugate 401. ***Peptide disclosed as SEQ ID NO: 40.***

Please delete the paragraph on page 45, line 19 and replace it with the following paragraph:

Figure 19 : Retrosynthetic analysis of the target conjugates 501,502, 503. ***Peptide disclosed as SEQ ID NO: 40.***

Please delete the paragraph on page 45, line 24 and replace it with the following paragraph:

Figure 24 : Retrosynthetic analysis of the target conjugates 601,602. **Peptide disclosed as SEQ ID NO: 40.**

Please delete the paragraph on page 45, line 29 and replace it with the following paragraph:

Figure 28bis: Synthesis of the conjugate 801. **Peptide disclosed as SEQ ID NO: 40.**